NOVEL HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7
申请人:Pragma Therapeutics
公开号:EP3459939A1
公开(公告)日:2019-03-27
The present invention relates to novel heterocyclic compounds. The invention is also directed to compounds which are modulators of the metabotropic glutamate receptors (mGluR), preferably of the metabotropic glutamate receptor subtype 7 ("mGluR7"). The present invention also relates to pharmaceutical composition comprising such compound and their use for the treatment of prevention of disorders associated with glutamate dysfunction.
A practical route to arylated dihydroacridine derivatives <i>via</i> nickel boride mediated intramolecular reductive cyclization-concomitant dehydration
作者:Rumpa Sarkar、Surya Kanta Samanta、Avantika Hasija、Deepak Chopra、Debabani Ganguly、Mrinal K. Bera
DOI:10.1039/d1nj05196b
日期:——
efficient route towards 3-aryl-1,2-dihydroacridine derivatives from an aldol adduct of o-nitrobenzaldehyde and cyclohexenone derivatives has been described. In situ generated nickel boride was found to be an excellent reagent to construct the acridine framework via an intramolecularreductive cyclization reaction at ambient temperature under acid-free conditions. The reaction is proved to be compatible